The relevance of T-type calcium antagonists: A profile of mibefradil

Journal of Clinical Pharmacology

Volumn 38, Issue 8, 1998, Pages 659-669

  Glasser, Stephen P ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL; CYTOCHROME P450; MIBEFRADIL;

ANGINA PECTORIS; BLOOD PRESSURE REGULATION; CALCIUM TRANSPORT; CARDIOVASCULAR SYSTEM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; ESSENTIAL HYPERTENSION; HEART ARRHYTHMIA; HEART RATE; HUMAN; INOTROPISM; MEMBRANE CHANNEL; PLASMA HALF LIFE; REVIEW; SUPRAVENTRICULAR TACHYCARDIA;

EID: 0031813302     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04804.x     Document Type: Review

References (58)

1. 2+ signaling in the cardiovascular system. Am J Cardial 1996;78(suppl 9A):2-6.
2. Katz AM: Cardiac ion channels. N Engl J Med 1993;328:1244-1251.
3. Catterall WA, Striessnig J: Receptor sites for Ca2+ channel antagonists. Trends Pharmacol Sci 1992;13:256-262.
4. Nayler WG: The molecular biology of the voltage-dependent, calcium antagonist-sensitive calcium channels. In, Nayler WG: Second Generation of Calcium Antagonists. New York: Springer-Verlag, 1991;25-37.
5. Arisizabal D, Frohlich ED: Calcium antagonists. In, Singh BN, Vanhoutte PM, Dzau VJ, Woosley RL (eds.): Cardiovascular Pharmacology and Therapeutics. New York: Churchill Livingstone, 1994;185-202.
6. Bean BP: Classes of calcium channels in vertebrate cells. Annu Rev Physiol 1989;51:367-384.
7. Tsien RW, Tsien RY: Calcium channels, stores, and oscillations. Annu Rev Cell Biol 1990;6:715-760.
8. Slish DF, Schultz D, Schwartz A: Molecular biology of the calcium antagonist receptor. Hypertension 1992;19:19-24.
9. 2+ current in single canine Purkinje cells. Circ Res 1989;65:1735-1750.
10. Chen C, Corbley MJ, Roberts TM, Hess P: Voltage-sensitive calcium channels in normal and transformed 313 fibroblasts. Science 1988;239:1024-1026.
11. Lotan I, Goelet P, Gigi A, Dascal N: Specific block of calcium channel expression by a fragment dihydropyridine receptors cDNA. Science 1989;243:666-669.
12. Bogdanov KY, Ziman BD, Spurgeion HA, Lakatta EG: L-and T-type calcium current differ in finch and rat ventricular cardiomyocytes. J Mol Cell Cardiol 1995;27:2581-2593.
13. 2+ channels in guinea pig hearts. J Physiol 1992;456:247-265.
14. 2+ channels by RO40-5967. Circ Res 1994;75:144-148.
15. Bernink JLM, Prager G, Schelling A, Kobrin I: Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Hypertension 1996;27:426-432.
16. Estacion M, Mordan LJ: Expression of voltage-gated calcium channels correlates with PDGF-stimulated calcium influx and depends upon cell density in C3H 10T1/2 mouse fibroblasts. Cell Calcium 1993;14:161-171.
17. Wilde DW, Furspan PB, Szocik JF: Calcium current in smooth muscle cells from normotensive and genetically hypertensive rats. Hypertension 1994;24:739-749.
18. Kelly RA, Eid H, Kramer BK: Endothelin enhances the contractile responsiveness of adult rat ventricular myocytes to calcium by a pertussis toxin-sensitive pathway. J Clin Invest 1990: 86:1164-1171.
19. Furukawa T, Ito H, Nitta J, Tsusino M, Adadi S, Hiroe M, et al: Endothelin-I enhances calcium entry through T-type calcium channels in cultured neonatat rat ventricular myocytes. Circ Res 1992;71:1242-1253.
20. Beuckelmann DJ, Nabauer M, Enimann E: Characteristics of calcium-current in isolated human ventricular myocytes from patients with terminal heart failure. J Mol Cell Cardiol 1991;23: 929-937.
21. 2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res 1993;73:777-782.
22. Satoh H: Role of T-type Ca channel inhibitors in the pacemaker depolarization in rabbit sinoatrial nodal cells. Gen Pharmacol 1995;25:581-587.
23. Kito M, Maehara M, Watanabe K: Antiepileptic drugs-calcium current interaction in cultured human neuroblastoma cells. Seizure, 1994;3:141-149.
24. Suzuki S, Rogawski MA: T-type calcium channels mediate the transition between tonic and phasic firing in thalamic neurons. Proc Natl Adad Sd U S A 1989;86:7228-7232.
25. Suzuki S, Kawakami K, Nishimura S, Watanabe Y, Yagi K, Seino MM: Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992;12:21-27.
26. 2+ influx via T-type channels modulates PDGF-induced replication of mouse fibroblasts. Am J Physiol 1993;265:C1239-C1246.
27. Tseng G-Y, Boyden PA: Different effects of intracellular Ca and protein kinase C on cardiac T and L currents. Am J Physiol 1991;261:H364-H379.
28. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T: The angiotensin AT2-receptor medicates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995;95:651-657.
29. McCarthy RT, Isales C, Rasmussen H: T-type calcium channels in adrenal glomerulosa cells: GTP-dependent modulation by angiotensin II. Proc Natl Acad Sci U S A 1993;90:3260-3264.
30. Schmitt R, Clozel J-P, Iberg N, Buhler FR: Mibefradil prevents neointima formation after vascular injury in rats: possible role of the blockade of T-type voltage-operated calcium channel. Arterioscler Thromb Vasc Biol 1995;15:1161-1165.
31. Franco-Obregon A, Urena J, Lopez-Bamen J: Oxygen-sensitive calcium channels in vascular smooth muscle and their possible role in hypoxic arterial relaxation. Proc Natl Acad Sci U S A 1995;92:4715-4719.
32. Clozel J-P, Banken L, Osterrieder W: Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil. J Cardiovasc Pharmacol 1989;14: 713-721.
33. 3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther 1990;4:731-736.
34. Schmitt R, Kleinbloesem CH, Belz GG, Schroeter V, Feifes U, Pazenel H, et al: Hemodynamic and humoral effect of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther 1992;52:314-323.
35. Portegies MCM, Schmitt R, Kraaij CJ, Braab SHJG, Gassner A, Hagemiejer F, et al: Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris. J Cardiovasc Pharmacol 1991;18:746-751.
36. Chapelle F, Stoleru L, Hayashida W: Ro 40-5967, a new calcium antagonist profile bradycardia without myocardial depress? (abstract). Circulation 1994;4:1928.
37. Levine TB: The design of the Mortality Assessment in Congestive Heart Failure trial (MACH-I), mibefradil. Clin Cardiol 1997;20:320-326.
38. Rosenquist M, Brembilla-Perrot B, Meinertz T, Neugebauer A, Crijns HJ, Smeets JL, et al: The acute effects of intravenously administered mibefradil, a new calcium antagonist, on the electrophysiologic characteristics of the human heart. Eur J Clin Pharmacol 1997;52:7-12.
39. Billman GE, Hamlin RL: The effects of mibefradil, a novel calcium channel antagonist on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation. J Pharmacol Exp Ther 1996;227:1517-1526.
40. Bakx LM, van der Wall EE, Braun S, Emanuelsson H, Bruschke AVG, Kobrin I, on behalf of the Ro 40-5967 International Study Group: Effect of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multi-center, placebo-controlled study. Am Heart J 1995;130:748-757.
41. Braun S, van der Wall E, Emanuelsson H, Kobrin I: Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multi center placebo-controlled study. J Am Coll Cardiol 1996;27:317-322.
42. Tzivoni D, Kadr H, Braat S, Rutsch W, Ramires JA, Kobrin I: Efficacy of mibefradil compared with amlodipine in suppressing exercise-incuded and daily silent ischemia: results of a multi center, placebo-controlled trial. Circulation 1997;96:2557-2564.
43. 2+ channel blocker with potent vasodilator but weak inotropic action. J Cardiovasc Pharmacol 1989;13:754-759.
44. Oparil S, Bernink P, Bursztyn M, Carney S, Kobrin I: Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension. Am J Cardiol 1997;80:12C-19C.
45. Oparil S, Kobrin I, Abernethy DR, Levine BS, Reif MC, Shepherd AM: Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension. Am J Hypertens 1997;10:735-742.
46. Burstyn M, Kadr H, Tilvis R, Martina B, Oigman W, Talbert J, Kobrin I: Mibefradil, a novel calcium antagonist, in elderly patients with hypertension: favorable hemodynamics and pharmacokinetics. Am Heart J 1997;134:238-247.
47. Hoglund C, Lindberg E, Watt A, Wilkins MR, Tencer J, Cifkova R, Mimran A: A comparison of the effects of mibefradil and attenolol on left ventricular hypertrophy regression in hypertensive patients. J Cardiology (in press).
48. Physicians Drug Reference. Montvale, NJ: Medical Economics Data, 1998.
49. Carney S, Wing L, Riberiro A, Kallwellis R, Zimlichman R, Viskoper RJ, et al: The addition of mibefradil in chronic hydrochlorothiazide therapy in hypertensive patients is associated with a significant antihypertensive effect. J Hum Hypertens 1997;11: 459-466.
50. Massie BM, Lacourciere Y, Viskoper R, Woittiez A, Kobrin I: Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists. Am J Cardiol 1997; 80:27C-33C.
51. Villa G, Sega R, Fogari R, Gaudeul P, Pordy R: The antihypertensive efficacy and safety of mibefradil in comparison with enalapril in patients with mild to moderate hypertension. Eur J Intern Med (in press).
52. Peters J, Viskoper R, Chen C, Welker HA: Pharmacokinetics and clinical effects of mibefradil alone and in combination with atenolol. Br J Clin Pharmacol (in press).
53. Davies GJ, Tzivoni D, Kobrin I: Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists. Am J Cardiol 1997;80:34C-39C.
54. Schneeweiss A, Kobrin I, Charlon V, Caspi A, Marmor A, Sclarovsky S, et al: Adding the new calcium antagonist mibefradil to patients receiving long-term beta-blocker therapy results in improved antianginal and anti-ischemic efficacy. Am Heart J 1998;135:272-280.
55. Alpert JS, Bakx AL, Braun S, Frishman WH, Schneeweiss A, Tzivoni D, Kobrin I: Antianginal and anti-ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris. Am J Cardiol 1997;80:20C-26C.
56. Triggle D: Sites, mechanism of action, and differentiation of calcium channel antagonists. Am J Hypertens 1991;4:422S-429S.
57. Triggle D: Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist. Am J Cardiol 1996;7(suppl 9A):7-12.
58. Clozel JP, Osterrieder W, Kleinbloesem CH, Welker HA, Schlappi B, Tudor R, et al: Ro 40-5967: a new non-dihyropyridine calcium antagonist. Cardiovasc Drug Rev 1991;9:4-17.